Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Can-Fite Biopharma Ltd ADR (CANF)

Can-Fite Biopharma Ltd ADR (CANF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Can-Fite BioPharma Announces Special Shareholder Meeting for Capital Restructuring Tipranks - Sat Oct 4, 3:58PM CDT

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. An announcement...

CANF : 0.3390 (-0.88%)
bioAffinity Technologies and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ACCESS Newswire - Fri Mar 28, 4:00AM CDT

ORLANDO, FLORIDA / ACCESS Newswire / March 28, 2025 / RedChip Companies will air interviews with bioAffinity Technologies, Inc. (Nasdaq:BIAF) and Can-Fite BioPharma Ltd. (NYSE American:CANF) on the RedChip...

BIAF : 1.7200 (+9.55%)
CANF : 0.3390 (-0.88%)
Can-Fite BioPharma Reports 8-Year Survival with Namodenoson in Liver Cancer Patient and Announces Phase III Study Enrollment Quiver Quantitative, Inc. - Wed Dec 4, 2024

Can-Fite announces an 8-year complete response in advanced liver cancer patient treated with Namodenoson; Phase III study enrolling now.Quiver AI SummaryCan-Fite BioPharma Ltd. announced promising results...

CANF : 0.3390 (-0.88%)
60 Degrees Pharmaceuticals and Can-Fite BioPharma Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV ACCESS Newswire - Fri Nov 22, 2024

ORLANDO, FL / ACCESSWIRE / November 22, 2024 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (Nasdaq:SXTP) and Can-Fite BioPharma Ltd. (NYSE American:CANF)(TASE:CANF) on the...

SXTP : 0.9801 (-3.91%)
CANF : 0.3390 (-0.88%)
Can-Fite BioPharma, Ltd. to Present at the LD Micro Invitational XIV Newsfile - Mon Apr 1, 2024

Ramat Gan, Israel--(Newsfile Corp. - April 1, 2024) - Can-Fite BioPharma, Ltd. (NYSE American: CANF) announced today that it will be presenting at The 14th Annual LD Micro Invitational at the Sofitel New...

CANF : 0.3390 (-0.88%)
Happy Thanksgiving, Uncle Sam! Baystreet - Fri Nov 17, 2023

Monday U.S. Economic Lookahead U.S. leading economic indicators (Oct.) Featured Earnings Agilent ...

A : 148.32 (-0.63%)
NVDA : 183.38 (+2.11%)
DE : 483.03 (+0.25%)
CANF : 0.3390 (-0.88%)
TCOM : 71.12 (+0.57%)
LOW : 246.17 (-0.31%)
KEYS : 209.07 (+1.19%)
GDS : 33.78 (+0.12%)
BMA : 88.28 (+0.20%)
HTHT : 47.20 (-0.17%)
LEXX : 1.1200 (+0.90%)
WN.TO : 95.85 (+0.96%)
Author
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding MarketBeat - Tue May 2, 2023

Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers

MRK : 100.89 (-1.35%)
LLY : 1,014.49 (-1.85%)
CANF : 0.3390 (-0.88%)
BMY : 51.95 (+1.94%)
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists Business Wire - Tue May 2, 2023

Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 0.3390 (-0.88%)
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization Business Wire - Mon Apr 24, 2023

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 0.3390 (-0.88%)
Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment Business Wire - Mon Apr 10, 2023

Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today...

CANF : 0.3390 (-0.88%)

Barchart Exclusives

Is This Dividend Stock a Buy for 2026 After Rising 265% in 2025? Barchart - Thu Dec 4, 6:30PM CST
Anglogold Ashanti shares have soared this year amid a spike in gold prices. While the shares might take a breather for now, it is a buy-on-the-dip candidate for 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot